[go: up one dir, main page]

WO2008144754A3 - Methods of treating inflammatory disorders using isoforms of receptor tyrosine kinases - Google Patents

Methods of treating inflammatory disorders using isoforms of receptor tyrosine kinases Download PDF

Info

Publication number
WO2008144754A3
WO2008144754A3 PCT/US2008/064415 US2008064415W WO2008144754A3 WO 2008144754 A3 WO2008144754 A3 WO 2008144754A3 US 2008064415 W US2008064415 W US 2008064415W WO 2008144754 A3 WO2008144754 A3 WO 2008144754A3
Authority
WO
WIPO (PCT)
Prior art keywords
isoforms
receptor tyrosine
tyrosine kinases
methods
inflammatory disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/064415
Other languages
French (fr)
Other versions
WO2008144754A2 (en
Inventor
H Michael Shepard
Pei Jin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptor Biologix Inc
Original Assignee
Receptor Biologix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptor Biologix Inc filed Critical Receptor Biologix Inc
Publication of WO2008144754A2 publication Critical patent/WO2008144754A2/en
Publication of WO2008144754A3 publication Critical patent/WO2008144754A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides methods, compositions, and kits for treatment of inflammatory joint disorders, such as rheumatoid arthritis, using polypeptide isoforms of receptor tyrosine kinases (RTKs), such as Tie-1, FGF-Rl, VEGF- R2, and HER-2, and nucleic acids encoding such RTK isoforms.
PCT/US2008/064415 2007-05-21 2008-05-21 Methods of treating inflammatory disorders using isoforms of receptor tyrosine kinases Ceased WO2008144754A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93931707P 2007-05-21 2007-05-21
US60/939,317 2007-05-21

Publications (2)

Publication Number Publication Date
WO2008144754A2 WO2008144754A2 (en) 2008-11-27
WO2008144754A3 true WO2008144754A3 (en) 2009-04-09

Family

ID=39866794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/064415 Ceased WO2008144754A2 (en) 2007-05-21 2008-05-21 Methods of treating inflammatory disorders using isoforms of receptor tyrosine kinases

Country Status (2)

Country Link
TW (1) TW200904466A (en)
WO (1) WO2008144754A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053059A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
WO2004110487A1 (en) * 2003-06-17 2004-12-23 Prochon Biotech Ltd. Treatment of t cell mediated diseases by inhibition of fgfr3
WO2005016966A2 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
WO2005113596A2 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
US20070110752A1 (en) * 2002-05-28 2007-05-17 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053059A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
US20070110752A1 (en) * 2002-05-28 2007-05-17 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
WO2005016966A2 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
WO2004110487A1 (en) * 2003-06-17 2004-12-23 Prochon Biotech Ltd. Treatment of t cell mediated diseases by inhibition of fgfr3
WO2005113596A2 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIN P ET AL: "Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis", ARTHRITIS RESEARCH AND THERAPY 20080701 GB, vol. 10, no. 4, 1 July 2008 (2008-07-01), XP021041240, ISSN: 1478-6354 1478-6362 *

Also Published As

Publication number Publication date
TW200904466A (en) 2009-02-01
WO2008144754A2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2005080429A3 (en) Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
MY147661A (en) Fused bicycloheterocycle substituted azabicyclic alkane derivatives
WO2008115732A3 (en) Anti-sclerostin antibodies
WO2007098420A3 (en) Peptides that block the binding of igg to fcrn
WO2007149427A3 (en) Tyrosine kinase inhibitors
GEP20094623B (en) Heteroaromatic quinoline compounds and their use as pde10 inhibitors
WO2007127317A3 (en) Humanized c-kit antibody
MX2010005648A (en) Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators.
WO2010129600A3 (en) Fgf21 mutants and uses thereof
WO2010129053A3 (en) Egfr inhibitors and methods of treating disorders
WO2003092595A3 (en) Tyrosine kinase inhibitors
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
WO2007076070A3 (en) Modulators of muscarinic receptors
JO3313B1 (en) Compositions and methods for increasing muscle growth
MX344733B (en) Activin receptor-like kinase-1 compositions and methods of use.
WO2008137622A3 (en) Aminopyrimidines useful as kinase inhibitors
MX368459B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
WO2013063458A3 (en) Inhibiting g protein coupled receptor 6 kinase polypeptides
WO2007100664A3 (en) Modulators of muscarinic receptors
WO2006096487A3 (en) Methods and compositions for modulating tweak and fn14 activity
WO2008011006A3 (en) Methods for treating pain and screening analgesic compounds
WO2006135839A3 (en) Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor
WO2007036945A3 (en) Hepatocyte growth factor receptor splice variants and methods of using same
WO2009117626A3 (en) Methods for making central nervous system agents that are trpv1 antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08756082

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08756082

Country of ref document: EP

Kind code of ref document: A2